<DOC>
	<DOCNO>NCT00401089</DOCNO>
	<brief_summary>The objective study determine whether Panax Ginseng multiple interaction key component brain signal pathway , augment effect antipsychotic Schizophrenia . We primarily interested examine action Ginseng combine antipsychotic improve way patient diagnose schizophrenia behave social environment , store , process retrieve information .</brief_summary>
	<brief_title>Efficacy Study Panax Ginseng Boost Antipsychotics Effects Schizophrenia</brief_title>
	<detailed_description>Schizophrenia serious mental disorder affect individual multiple way : behavior control , emotional information process functional level conform societal norm . Despite recent advance medication therapy treat target symptom schizophrenia , subsets patient diagnose schizophrenia continue exhibit negative symptom ( social withdrawal , apathy , lack drive ) cognitive impairment ( memory , attention , judgment reasoning ) . Recently , interest explore efficacy avenue dietary herbal supplement know pharmacological action treatment prevention neuropsychiatric disorder , especially bipolar schizophrenia . We hypothesize Panax Ginseng , multiple interaction chemical pathway brain describe neurotransmitter system ( Dopamine , GABA NMDA ) improve residual symptom schizophrenia add antipsychotic currently use treatment schizophrenia . Furthermore , view previous study Ginseng enhance memory , hypothesize standardized formulation Ginseng ( Ginsana-115 Boehringer Ingelheim-Pharmaton , Switzerland ) optimize antipsychotic cognition impairment negative symptom . In 18-week RCT cross-over study , schizophrenic subject treat either Ginsana-115 ( 100 mg 200 mg oral route ) placebo cross-over design . plan recruit 60 subject diagnose schizophrenia four site : London-St. Thomas , Ontario , Canada ; Kingston Ontario Canada ; Thunderbay , Ontario Canada Middlesex , United Kingdom .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Male female age 1865 year DSMIV diagnosis Schizophrenia SANS score great 30 Current ( past 12 month ) substance use disorder Except nicotine dependence Major medical disorder : hematological disorder Chronic active hepatitis , acute hepatitis , cirrhosis liver , AIDS Pregnancy breastfeed Neurological disorder include epilepsy traumatic brain injury HAMD score great 24</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>negative symptom schizophrenia</keyword>
	<keyword>Atypical antipsychotic</keyword>
	<keyword>Neurocognition impairment</keyword>
	<keyword>obesity risk factor</keyword>
	<keyword>Diabetes insulin resistance schizophrenia</keyword>
</DOC>